Steady optimistic airway stress “is right here to remain,” sleep medication physician Atul Malhotra declared in a Might 2024 editorial printed within the Lancet.
However after Eli Lilly reported the total outcomes of its weight problems drug in sleep apnea sufferers final week, business watchers at the moment are debating the lasting energy of CPAP machines. The trial, run by Malhotra himself, demonstrated that Zepbound decreased the variety of sleep apnea episodes in sufferers each who had been utilizing the machines and people who weren’t.
Buyers swiftly reacted after the information launch on late Friday. On Monday, shares of main CPAP maker ResMed dropped 11% and shares of nerve stimulator Encourage sank 17%. However business analysts and medical specialists are cut up on whether or not that is one other instance of “Ozempic panic,” or a legit warning of CPAP’s eventual decline.
STAT+ Unique Story
Have already got an account? Log in
This text is unique to STAT+ subscribers
Unlock this text — and get further evaluation of the applied sciences disrupting well being care — by subscribing to STAT+.
Have already got an account? Log in
Have already got an account? Log in
Particular person plans
Group plans
View All Plans
Get limitless entry to award-winning journalism and unique occasions.
Subscribe